Related Posts
The new blood test is less invasive and more accessible to patients. Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE. Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response. Imlunestrant plus abemaciclib improved PFS across subgroups in ER+/HER2- breast cancer, per EMBER-3 data. Abemaciclib plus fulvestrant showed benefit across biomarkers after CDK4/6i failure in advanced HR+/HER2- breast cancer.